Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

    (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NVnRN3NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS4eFd7UUN3ME21Mlg3PjZizszN MmezV2FPT0WU
DOHH-2 NH7PZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjaTWM2OD17LkO1Olg6KM7:TR?= NWDjSIFvW0GQR1XS
no-10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXmTWM2OD17LkmwN|kh|ryP NILPSW9USU6JRWK=
LS-513 M37mN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHNSoNKSzVyPUGxMlM2PDdizszN MoDOV2FPT0WU
ALL-PO NYT3fVR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\2TWlEPTB;MUGuO|c{PCEQvF2= MVLTRW5ITVJ?
8-MG-BA M1LDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF|LkGxNlMh|ryP NETlS4tUSU6JRWK=
RPMI-8402 MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\NN4hKSzVyPUG1Mlg2OzdizszN MkPhV2FPT0WU
EoL-1-cell MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3TTWM2OD1zOD61PVQ5KM7:TR?= M2C5N3NCVkeHUh?=
NALM-6 NHHxWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XtZWlEPTB;MUmuNFE3PyEQvF2= NVLxeXZTW0GQR1XS
DEL Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjmWWtKSzVyPUKwMlE1PzFizszN NFL5VpFUSU6JRWK=
SR MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK3TWM2OD1{Mz62O|E2KM7:TR?= M2LnbnNCVkeHUh?=
697 NYDFZoRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofYTWM2OD1{Nj62NVU2KM7:TR?= NEXKd|hUSU6JRWK=
COLO-829 NYjPWHFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ4Lki0PFMh|ryP NE\5T4FUSU6JRWK=
EVSA-T NXfCc3ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Dv[GlEPTB;MkeuOVU3OSEQvF2= M1HFfXNCVkeHUh?=
ATN-1 NGO5dZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTNzLkKzNlkh|ryP MorsV2FPT0WU
L-363 M1\3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:wb|lKSzVyPUOxMlc1PjFizszN MomyV2FPT0WU
LAMA-84 M4\iWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\M[nduUUN3ME2zNk42OjFzIN88US=> MXnTRW5ITVJ?
NOS-1 M4XmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUS1dmduUUN3ME2zOE4zQTV4IN88US=> M3;TW3NCVkeHUh?=
BB30-HNC MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX4TWM2OD1|ND6zN|A3KM7:TR?= M13DS3NCVkeHUh?=
BC-1 MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PocGlEPTB;M{euPVc1PiEQvF2= MnzMV2FPT0WU
IST-SL2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzJWlZ3UUN3ME2zPE4zOjRizszN M1O1[nNCVkeHUh?=
D-392MG M3f1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvCPVB7UUN3ME20NE4zOjF3IN88US=> NGPzepFUSU6JRWK=
no-11 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP2TWM2OD12MD61OVIyKM7:TR?= NUi3cm11W0GQR1XS
LC4-1 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTRyLki3NVYh|ryP NV:wWmk{W0GQR1XS
A388 NV\TfItkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDLc5N{UUN3ME20Nk42QDR6IN88US=> NHrqcZdUSU6JRWK=
NTERA-S-cl-D1 NXW0OHJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTIcGJ{UUN3ME20Nk44ODd2IN88US=> NH3uWFBUSU6JRWK=
CESS MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TuNGlEPTB;NESuNlI{OiEQvF2= Mnv3V2FPT0WU
RS4-11 M4rrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPhcpRKSzVyPUS5MlA6OzhizszN NHvBZVlUSU6JRWK=
MS-1 NYjIc2k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7sTWM2OD13MD65N|UyKM7:TR?= MVnTRW5ITVJ?
CTV-1 M4fWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTVzLkC3OEDPxE1? M1P6fHNCVkeHUh?=
D-502MG NYLESWV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHLXG9oUUN3ME21NU43OjdzIN88US=> MkHkV2FPT0WU
ML-2 M1fNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTV{LkmxPVUh|ryP M1X5ZXNCVkeHUh?=
SK-NEP-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PTNGlEPTB;NUOuN|kzOyEQvF2= NYrETIVrW0GQR1XS
LOXIMVI MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XsSWlEPTB;NUOuOVg5PCEQvF2= MX\TRW5ITVJ?
DJM-1 NXnL[JJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTV4LkOzPVEh|ryP MX\TRW5ITVJ?
GI-1 NIqxdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rjXGlEPTB;NU[uOlE1QSEQvF2= NVHTPFVQW0GQR1XS
IST-MES1 NUKweHZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS3ZlMzUUN3ME22NE42PDl|IN88US=> NYLub3NuW0GQR1XS
MV-4-11 MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLQTWcyUUN3ME22NE43PTN6IN88US=> MYXTRW5ITVJ?
OVCAR-4 NHXFbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlToTWM2OD14Mz61OlU4KM7:TR?= MoTNV2FPT0WU
KE-37 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPjVGJXUUN3ME22Ok4zPjZ6IN88US=> M2\iSHNCVkeHUh?=
D-542MG NV72WmR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfiTWM2OD14OD60NVM2KM7:TR?= MVfTRW5ITVJ?
MHH-PREB-1 NIK5eYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[zfYRyUUN3ME23Nk45PDRzIN88US=> NVvPcXR5W0GQR1XS
MRK-nu-1 M1vwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\rVY9iUUN3ME23N{41PzB3IN88US=> MmrWV2FPT0WU
D-247MG M{jx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf2TWM2OD15Mz61OFQzKM7:TR?= MoHXV2FPT0WU
OCI-AML2 NFX5V4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTd4LkmzOlkh|ryP M1\wWXNCVkeHUh?=
LP-1 M2DHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXRTWM2OD16Mj64O|MyKM7:TR?= MkfHV2FPT0WU
HCC1599 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTh2LkK4N|ch|ryP MUnTRW5ITVJ?
KARPAS-45 Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDkSG1VUUN3ME24OE43QTl{IN88US=> MWHTRW5ITVJ?
BE-13 MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PjSmlEPTB;OUmuNFQ4PyEQvF2= M1;DT3NCVkeHUh?=
GCIY MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDGTWM2OD17OT6wPVU1KM7:TR?= NYixUXd{W0GQR1XS
BV-173 NVTLN4M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rDdmlEPTB;MUCwMlMzPSEQvF2= M2XWXnNCVkeHUh?=
LB2518-MEL M1;MXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX2TWM2OD1zMECuO|g6KM7:TR?= NH3DdXJUSU6JRWK=
KS-1 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG4Vm1KSzVyPUGwNU43OzlizszN MUHTRW5ITVJ?
MOLT-16 NVToVGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfoZllKSzVyPUGwOE46QDZizszN M{TEdXNCVkeHUh?=
NCI-H1770 NX\qbFZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\DZWlEPTB;MUC4Mlc5PCEQvF2= MnH1V2FPT0WU
NCI-H82 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPGTWM2OD1zMUCuPVc3KM7:TR?= M3fIUHNCVkeHUh?=
NCCIT NWCzZXFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\TT3VtUUN3ME2xNVIvPTJ7IN88US=> NI\QUYZUSU6JRWK=
KALS-1 M2nUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFzNT65OFEh|ryP MUjTRW5ITVJ?
LB2241-RCC M{TYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3HUG1KSzVyPUGxOk43PzlizszN M3TBTXNCVkeHUh?=
HH Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILBVI1KSzVyPUGxO{4{QTVizszN NY\oe4FVW0GQR1XS
HD-MY-Z MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonlTWM2OD1zMUiuOFg5KM7:TR?= NVjtTFZmW0GQR1XS
EB-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK1[mFKSzVyPUGyN{4xQTRizszN NWDC[4Q3W0GQR1XS
BL-70 M1\GWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;DTI1kUUN3ME2xNlMvOTJ5IN88US=> M37jUnNCVkeHUh?=
K-562 M3H3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO3cWE4UUN3ME2xNlYvOjR3IN88US=> NGrvfWRUSU6JRWK=
HT-144 MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnzS4wxUUN3ME2xN|MvOTZ2IN88US=> MYTTRW5ITVJ?
PF-382 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjW[2VKSzVyPUGzOE4{PjFizszN MkXJV2FPT0WU
RPMI-8226 M1ToNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjibFZKSzVyPUGzOU4xPDVizszN M2nTc3NCVkeHUh?=
NCI-H1355 NWXVWXp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzxdHZJUUN3ME2xN|UvPTh5IN88US=> MU\TRW5ITVJ?
LXF-289 M3e4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fxUmlEPTB;MUO5Mlc5OSEQvF2= M{nUb3NCVkeHUh?=
NCI-H69 NF;GRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkOzTWM2OD1zNEKuPVMzKM7:TR?= MmHlV2FPT0WU
SK-MEL-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTKTWM2OD1zNEeuNVMh|ryP NXzkcmdmW0GQR1XS
KARPAS-299 MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrRTWM2OD1zNEmuNVIh|ryP NFHHbmNUSU6JRWK=
GB-1 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHadm9zUUN3ME2xOFkvOzJ{IN88US=> NX;n[phJW0GQR1XS
CMK M3i4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ZR2lEPTB;MUS5MlUyPSEQvF2= NXnTdHBXW0GQR1XS
MPP-89 NXHE[I1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrkTWM2OD1zNU[uNFM2KM7:TR?= M2nJRnNCVkeHUh?=
KU812 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLBTWM2OD1zNkGuPVAzKM7:TR?= NYPvfXNTW0GQR1XS
REH MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u2NWlEPTB;MU[yMlEzPSEQvF2= NHvuNo1USU6JRWK=
NEC8 NYHneXoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly0TWM2OD1zNkWuNFI3KM7:TR?= MYfTRW5ITVJ?
KP-N-YS MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF4OD6zPVUh|ryP MX7TRW5ITVJ?
Ramos-2G6-4C10 NXvocYp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi0[VNKSzVyPUG2PU46OTVizszN NG[5eYNUSU6JRWK=
Becker Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT3TWM2OD1zN{SuNVgh|ryP NVm0ZlBSW0GQR1XS
LB647-SCLC NUL1eFNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC1[4pKSzVyPUG3OU45PDVizszN MWjTRW5ITVJ?
LU-139 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPGWpZKSzVyPUG3PE4xOTlizszN NV\QTYhWW0GQR1XS
QIMR-WIL NVHEO3B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPITWM2OD1zN{muOlQ3KM7:TR?= NHTrWFZUSU6JRWK=
NCI-H1395 NUOzT3VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXjTm1KSzVyPUG3PU46QTZizszN MWfTRW5ITVJ?
NOMO-1 M33yfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j2[WlEPTB;MUiyMlg2KM7:TR?= MWfTRW5ITVJ?
GI-ME-N M3;WfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF6Nz65Olkh|ryP NHmzdG1USU6JRWK=
KMS-12-PE NG\FS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF6OT6yO|Mh|ryP MkTVV2FPT0WU
Daudi NV3F[nhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrnVHBKSzVyPUG5NU4yOjhizszN MmrKV2FPT0WU
LB996-RCC Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rTUWlEPTB;MUmxMlY6QSEQvF2= NH3SNVZUSU6JRWK=
NCI-H2107 NVHrZ5NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XPTWlEPTB;MUmzMlc{QSEQvF2= MmXlV2FPT0WU
SK-PN-DW NG\RRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7tW3BKSzVyPUG5OE44OTlizszN M1XNXnNCVkeHUh?=
MC-CAR NXi1co9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnB[JBLUUN3ME2yNFIvOjV|IN88US=> MYnTRW5ITVJ?
SNB75 NGq0[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ{MT65OEDPxE1? M1rzN3NCVkeHUh?=
ES4 MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC5TWM2OD1{MkOuO|g{KM7:TR?= MYPTRW5ITVJ?
KARPAS-422 MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDYT5A6UUN3ME2yNlgvOzV{IN88US=> M4\4SXNCVkeHUh?=
NCI-H1648 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm3TWM2OD1{MkmuOFg6KM7:TR?= NYT4TGprW0GQR1XS
ES6 NYLiSYI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu4VlU4UUN3ME2yN|kvPDNizszN MnzBV2FPT0WU
KNS-81-FD NWDQN|ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTjTWM2OD1{NEGuNVk4KM7:TR?= NWS1W2t5W0GQR1XS
JAR NHvWeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rENGlEPTB;MkW2MlIzPSEQvF2= MoDSV2FPT0WU
NB1 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS1OWR{UUN3ME2yOlAvPTF4IN88US=> NFn2bodUSU6JRWK=
D-336MG NXzmXIY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorWTWM2OD1{NkCuOlk5KM7:TR?= MmLOV2FPT0WU
BC-3 Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\sN2lEPTB;Mk[1MlE4QCEQvF2= M{TEUHNCVkeHUh?=
HCC2218 M2C0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfkTWM2OD1{Nk[uOFE2KM7:TR?= NGnvXZlUSU6JRWK=
TE-9 NVHWd402T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn0dYFiUUN3ME2yOlYvPjJ5IN88US=> NInldVRUSU6JRWK=
LB1047-RCC NHTIPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXnTWM2OD1{Nk[uO|U{KM7:TR?= NGrLdm1USU6JRWK=
CTB-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJ4OT65O|Mh|ryP NVXRUWxtW0GQR1XS
NB7 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPTTWM2OD1{N{Gg{txO NVvUcFZIW0GQR1XS
ST486 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLYTWM2OD1{N{euOFEzKM7:TR?= NGnaSVZUSU6JRWK=
HCC1187 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPJTWM2OD1{OEKuPFEyKM7:TR?= NEHQTm1USU6JRWK=
NCI-SNU-16 NHPQc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXwU5lKSzVyPUK4OE4zPDhizszN NIrBcmtUSU6JRWK=
COR-L279 NXfLbVhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXtTWM2OD1{OUGuOVg1KM7:TR?= MoTwV2FPT0WU
ES8 NXrZRm1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XKbGlEPTB;Mkm0MlE5OiEQvF2= NIHSO|NUSU6JRWK=
U-698-M M{HyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvLTWM2OD1{OUiuNlQ{KM7:TR?= Mkm5V2FPT0WU
HEL M{PrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrvTlRTUUN3ME2zNFkvOTR7IN88US=> MYXTRW5ITVJ?
KINGS-1 MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLwUW9KSzVyPUOxNE43PzRizszN M{PmdHNCVkeHUh?=
KY821 NIjWO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjjTWM2OD1|M{[uOVk2KM7:TR?= MXzTRW5ITVJ?
MZ1-PC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn3ZWdKSzVyPUO0OU43OThizszN M2rjOnNCVkeHUh?=
LS-411N NWXjOW5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjPUW5JUUN3ME2zOVQvPjZizszN MX3TRW5ITVJ?
SIG-M5 MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPlTWM2OD1|NUmuO|gzKM7:TR?= NVrPeohUW0GQR1XS
HT MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLSTWM2OD1|NkeuO|EyKM7:TR?= NXXKeoJlW0GQR1XS
HC-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLzTWM2OD1|NkeuO|g4KM7:TR?= MkDpV2FPT0WU
NCI-H1694 NWjZRoJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPzTWM2OD1|N{KuPVM1KM7:TR?= M1HKOHNCVkeHUh?=
BB65-RCC MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHNRnFKSzVyPUO3Ok4zPDVizszN NX[5epBVW0GQR1XS
HAL-01 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1exVmlEPTB;M{e5Mlg{QCEQvF2= MlnhV2FPT0WU
ARH-77 M2\0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrNbJl7UUN3ME2zPVQvODB6IN88US=> NWrrXmU6W0GQR1XS
MZ7-mel MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLrTWM2OD1|OUeuNlM{KM7:TR?= M3T0dHNCVkeHUh?=
SIMA M1[3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPDd25{UUN3ME20NFMvQTN|IN88US=> NWLPcmt4W0GQR1XS
DG-75 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XHU2lEPTB;NEG1MlY6QCEQvF2= M1HPUHNCVkeHUh?=
HUTU-80 NYrINXNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfXNGpKSzVyPUSxPU4yQDVizszN Ml65V2FPT0WU
KNS-42 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;NdnlKSzVyPUSyOU45OTVizszN NX3qVlViW0GQR1XS
SH-4 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\hTWM2OD12MkeuOVY2KM7:TR?= NYPVO4ZTW0GQR1XS
L-540 M1vK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;sOW1KSzVyPUSzNU4xOzFizszN MXzTRW5ITVJ?
NB10 NHP1S3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTvTWM2OD12NEGuNlM1KM7:TR?= M3nwfnNCVkeHUh?=
ES1 MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LPdmlEPTB;NEWyMlc2OyEQvF2= NYW5U4tzW0GQR1XS
KMOE-2 M{e2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTR3Nj63NVEh|ryP NH\5WZBUSU6JRWK=
MC116 M{ntemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLBSop[UUN3ME20OVgvOTF4IN88US=> NGf0PG1USU6JRWK=
RCC10RGB NVTDdXR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPVOlZbUUN3ME20OlAvODB3IN88US=> M1HJSXNCVkeHUh?=
RL95-2 NWL2T294T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7YTWM2OD12NkCuNlM4KM7:TR?= NHXPdldUSU6JRWK=
Raji NYS5WJhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfIOIRKSzVyPUS2PE4yPDNizszN Moi0V2FPT0WU
CAS-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\TTmlEPTB;NEeyMlA4OyEQvF2= MV3TRW5ITVJ?
Calu-6 NX3CSpZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTR5NT6yOlUh|ryP NFzjb|ZUSU6JRWK=
KG-1 NI\kNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1OxfWlEPTB;NEe4MlQ1KM7:TR?= M{Xr[3NCVkeHUh?=
LB771-HNC NX3lS2duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH1RZFKSzVyPUS4Nk4zOzJizszN MXrTRW5ITVJ?
ACN M3PBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTR7Mz61PVkh|ryP NHjvUo5USU6JRWK=
KM12 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDHZnE{UUN3ME20PVYvPTh7IN88US=> MV7TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products4

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID